# Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

> **NCT00707850** · PHASE4 · COMPLETED · sponsor: **Baqiyatallah Medical Sciences University** · enrollment: 300 (estimated)

## Conditions studied

- Hepatitis C
- Thalassemia

## Interventions

- **DRUG:** PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)

## Key facts

- **NCT ID:** NCT00707850
- **Lead sponsor:** Baqiyatallah Medical Sciences University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2010-08-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00707850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00707850, "Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00707850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*